BB BIOTECH AG

  • WKN: A0NFN3
  • ISIN: CH0038389992
  • Land: Switzerland

Nachricht vom 21.03.2019 | 17:40

BB BIOTECH AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.05

DGAP-News: BB BIOTECH AG / Key word(s): AGM/EGM

21.03.2019 / 17:40
The issuer is solely responsible for the content of this announcement.


Media Release as of March 21, 2019

BB Biotech AG: Shareholders at the general meeting vote in favor of all proposals and approve the dividend of CHF 3.05

All proposals of BB Biotech AG's Board of Directors were approved by shareholders at its Annual General Meeting held today.

Shareholders voted in favor of the proposal to pay out a dividend of CHF 3.05 per share. Payment will be made on March 27, 2019, the date of record is March 26, 2019 and the ex-dividend date is March 25, 2019.

Shareholders elected the previous board members Dr. Erich Hunziker, Chairman, Dr. Clive Meanwell and Prof. Dr. Dr. Klaus Strein to another one-year term of office. Dr. Thomas von Planta was newly elected to the Board of Directors.

Thomas von Planta brings profound expertise from the financial sector to the Board of Directors. He has been the business owner and manager of CorFinAd AG since 2006, a Zurich-based consultancy for M&A and capital market transactions. Prior to that he worked for Vontobel Group as Head Investment Banking a.i. and Head Corporate Finance and served on its Extended Executive Board. He was Chairman of the Board of Directors of Bellevue Group AG and was not standing for re-election at the Annual General Meeting on March 19, 2019. Thomas von Planta also sits on the Board of Directors of Bâloise Holding AG, Basel.


For further information:

Investor Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Dr. Silvia Siegfried-Schanz, ssc@bellevue.ch
Maria-Grazia Iten-Alderuccio, mga@bellevue.ch
Claude Mikkelsen, cmi@bellevue.ch

Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch

TE Communications AG, Bleichestrasse 11, 9000 St. Gallen, Switzerland, tel. +41 79 423 22 28
Thomas Egger, teg@te-communications.ch

www.bbbiotech.com

Company profile
BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Disclaimer
This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.



21.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Anleihe im Fokus

Ekosem-Agrar AG Anleihe: Jetzt noch bis zum 26. Juli 2019 zeichnen oder umtauschen!

Emissionsvolumen der 5-jährigen Anleihe bis zu 100 Mio. Euro, Zeichnungsfrist vom 28.06.- 26.07.2019 (voraussichtlich)


- WKN/ ISIN: A2YNR0 / DE000A2YNR0
- Stückelung: 1.000 Euro
- Kupon: 7,50 Prozent p.a.
- Laufzeit: 5 Jahre
- Rückzahlung: 1. August 2024 (Call Option ab 1. August 2021)
- Zinszahlung: Jährlich, jeweils am 1. August

Interview im Fokus

„Schnelleres Wachstum mit Wasserstoff“

Mit dem Einstieg in die Wasserstoff-Technologie erschließt sich SFC Energy ein besonders dynamisches Segment. „Mittelfristig ist das Marktvolumen für Wasserstoff-Brennstoffzellen noch größer als im Direkt-Methanol-Bereich. Zivile Massenanwendungen könnten sich dabei zu einem echten Wachstumsbooster entwickeln“, ist CEO Dr. Peter Podesser überzeugt. Im Financial.de-Interview spricht der SFC-Vorstandschef u. a. über die aktuelle Euphorie für Brennstoffzellen-Aktien, die geplante Kapitalmaßnahme und das mittelfristige Umsatzziel von 100 Mio. Euro.

GBC-Fokusbox

Studie GBC Best of m:access I.2019: Weiter im Aufwind und mit starker Outperformance

Das Qualitätssegment m:access hat sich in den letzten Jahren fulminant entwickelt und ist auch 2018 weiter gewachsen. Zuletzt umfasste der m:access einen Rekordwert von 60 Unternehmen unterschiedlichster Branchen mit einer Gesamtmarktkapitalisierung von rund EUR 12 Mrd. Der von GBC berechnete m:access Index hat im Betrachtungszeitraum eine starke Outperformance gezeigt. Auch für die neue Top 15 Best-Of-Auswahl sind die Analysten wieder sehr positiv gestimmt. Die Studie steht kostenlos zum Download zur Verfügung.

News im Fokus

Continental AG: Änderung der Prognose für das Geschäftsjahr 2019 und vorläufige Eckdaten für das zweite Quartal des Geschäftsjahres 2019

22. Juli 2019, 20:39

Aktueller Webcast

Westwing Group AG

Webcast H1 2019 Earnings Call

13. August 2019

Aktuelle Research-Studie

Adler Modemärkte AG

Original-Research: Adler Modemärkte AG (von Sphene Capital GmbH): Buy

23. Juli 2019